QGC001

DRUG3 trials

Sponsors

Quantum Genomics SA

Conditions

Essential HypertensionHeart FailureHypertension

Phase 2

Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension

CompletedNCT02322450

Quantum Genomics SAEssential Hypertension

Start: 2015-01-31End: 2016-04-30Updated: 2016-09-28

QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF

TerminatedNCT02780180

Quantum Genomics SAHeart Failure

Start: 2016-06-30End: 2018-09-12Updated: 2018-10-16

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

CompletedNCT03198793

Quantum Genomics SAHypertension

Start: 2017-10-13End: 2018-11-12Updated: 2018-12-11

Related Papers

Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins

Circulation2019-04-2473 citations

A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension

Journal of Hypertension2019-03-1940 citations